Theravance Biopharma (NASDAQ:TBPH) Shares Up 8.8% – Still a Buy?

Theravance Biopharma, Inc. (NASDAQ:TBPH) shares traded up 8.8% on Friday . The stock traded as high as $10.38 and last traded at $10.52. 145,699 shares were traded during mid-day trading, a decline of 17% from the average session volume of 174,689 shares. The stock had previously closed at $9.67.

Theravance Biopharma Stock Performance

The firm has a market cap of $518.99 million, a price-to-earnings ratio of -10.45 and a beta of 0.21. The business’s 50 day moving average price is $9.45 and its 200-day moving average price is $8.91.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). The business had revenue of $16.87 million during the quarter, compared to analyst estimates of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same period in the prior year, the firm earned ($0.17) EPS. On average, analysts forecast that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Monday, November 11th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now owns 322,743 shares in the company, valued at $2,904,687. This trade represents a 1.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 6.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Barclays PLC increased its stake in Theravance Biopharma by 279.9% in the third quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock valued at $529,000 after acquiring an additional 48,316 shares during the period. Squarepoint Ops LLC bought a new stake in Theravance Biopharma in the second quarter valued at $986,000. JPMorgan Chase & Co. raised its stake in Theravance Biopharma by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company’s stock worth $2,151,000 after acquiring an additional 7,620 shares in the last quarter. Bank of Montreal Can increased its position in shares of Theravance Biopharma by 141.0% during the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock worth $1,414,000 after purchasing an additional 93,702 shares in the last quarter. Finally, Algert Global LLC acquired a new position in Theravance Biopharma in the third quarter valued at about $851,000. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.